Bioethics News

Should Anyone Really Control Who Gets to Use CRISPR?

Last week, the US Patent and Trademarks office handed down a decision in one of the most high-profile patent cases of the century. In a one sentence ruling, an appeals board granted the rights to the powerful gene editing technology CRISPR-Cas9 to the Broad Institute of Harvard and MIT, while leaving the door open for rival CRISPR pioneer UC Berkeley to file a new patent to lay claim to those same discoveries

The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.